Integra LifeSciences price target lowered to $25 from $37 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Integra LifeSciences to $25 from $37 and keeps a Hold rating on the shares. The firm is adjusting its model to reflect the company’s further Boston facility restart delay, also removing its previously modeled contributions, the analyst tells investors in a research note. Integra’s Acclarent revenue offset the impact on the top line but not on margins, the firm states, adding that the stock’s valuation discount is justified given the accumulating execution errors on the part of the company as well as its peers’ faster revenue and growth prospects.